TrialAntimicrobial agents and chemotherapy2022

Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.

Margaret Gartland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.